<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082885</url>
  </required_header>
  <id_info>
    <org_study_id>Thymosin-α1</org_study_id>
    <nct_id>NCT03082885</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF</brief_title>
  <official_title>A Randomized Controlled Trial to Evaluate Efficacy and Safety of Thymosin-α1 Administration in Patients With HBV-related Acute-on-chronic Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled trial to evaluate efficacy and safety of Thymosin-α1 administration
      in patients with HBV-related Acute-on-chronic liver failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) is a severe disease
      with high mortality. In this study, the investigators intend to assess the efficacy and
      safety of Thymosin-α1 in patients with HBV-related Acute-on-chronic liver failure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Actual">July 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 2, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The liver transplantation-free survival rate of 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Survival condition of the patients were observed for 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The liver transplantation-free survival rate of 180 days</measure>
    <time_frame>180 days</time_frame>
    <description>Survival condition of the patients were observed for 180 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with ferver, bleeeding of injection site, amyotrophy and arthralgia</measure>
    <time_frame>24 weeks</time_frame>
    <description>Fever, bleeeding of injection site, amyotrophy and arthralgia were observed during the treatment in both group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications after 48 hours admission</measure>
    <time_frame>24 weeks</time_frame>
    <description>Occurence of encephalopathy, infection, bleeding,hepatorenal syndrome after 48 hours admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B virus DNA load change</measure>
    <time_frame>24 weeks</time_frame>
    <description>Hepatitis B virus DNA were measured on week 0, 4,8,12and 24 after the start of the infusion in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Causes of death/liver transplantation</measure>
    <time_frame>24 weeks</time_frame>
    <description>Causes of death/liver transplantation (e.g. liver failure, multiple organs failure, severe infection) were recorded in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory indexes change</measure>
    <time_frame>24 weeks</time_frame>
    <description>Inflammatory indexes were measured on week0,1,2, 4,8,12and 24 after the start of the infusion in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase change</measure>
    <time_frame>24 weeks</time_frame>
    <description>Levels of alanine aminotransferase were measured on week0,1,2, 4,8,12and 24 after the start of the infusion in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutamic oxaloacetic transaminase change</measure>
    <time_frame>24 weeks</time_frame>
    <description>Levels of glutamic oxaloacetic transaminase were measured on week0,1,2, 4,8,12and 24 after the start of the infusion in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bilirubin change</measure>
    <time_frame>24 weeks</time_frame>
    <description>Levels of total bilirubin were measured on week0,1,2, 4,8,12and 24 after the start of the infusion in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma thrombin time change</measure>
    <time_frame>24 weeks</time_frame>
    <description>Levels of plasma thrombin time were measured on week0,1,2, 4,8,12and 24 after the start of the infusion in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin time change</measure>
    <time_frame>24 weeks</time_frame>
    <description>Levels of albumin were measured on week0,1,2, 4,8,12and 24 after the start of the infusion in both groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>Thymosin-α1 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive treatment based on standard Therapy with additional Thymosin-α1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive treatment based on standard Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymosin-α1</intervention_name>
    <description>1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks.</description>
    <arm_group_label>Thymosin-α1 group</arm_group_label>
    <other_name>Zadaxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Chronic hepatitis B.(Hepatitis B surface antigen positive for more than 6 months or
             having evidence of chronic hepatitis B virus infection).

          -  2.Defined by an acute deterioration in transaminase greater than or equal to 5 times
             upper normal limit over14 days.

          -  3.Development of jaundice (serum bilirubin greater than or equal to 10mg/dl).

          -  More than one of the 4-8 criteria：

          -  4.Development of coagulopathy(PTA≤40% or INR≥1.5 ).

          -  5.Development of hepatic encephalopathy.

          -  6.Development of hepatorenal syndrome.

          -  7.Hepatic narrowing progressively.

          -  8.Development of massive ascites or peritonitis.

          -  9. Willing to provide informed consent and comply with the test requirements

        Exclusion Criteria:

          -  1.Patients who have hepatocellular carcinoma confirmed by ultrasound/CT/MR.

          -  2.Patients who have autoimmune disease (such as inflammatory bowel disease, idiopathic
             thrombocytopenic purpura, systemic lupus erythematosus, etc ) or with abnormal
             elevation level of autoimmune antibody.

          -  3.Patients with significant co-morbid illnesses such as cardiovascular or respiratory
             or intrinsic renal diseases which by themselves may have a bearing on the outcome.

          -  4.Patients with diseases that researchers consider inappropriate to participate in the
             study.

          -  5.Patients who have disseminated intravascular coagulation.

          -  6.Drug allergy.

          -  7.Patients with any other contraindications to thymosin alpha1.

          -  8.Patients who participated in other clinical trials at the same time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin B Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>leading</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Third Affliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Lin Bingliang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

